Existing data show that recurrence patterns vary among cancer subtypes: ER-positive tumours, both luminal A and B, show an increase in recurrence risk over time, while triple-negative and HER2-positive tumours tend to recur within the first 5 years [11,12,13]. This evidence concerns the gene ERBB2 and cancer.